Synapse - Works

Results (4640)

Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations

Meeting Abstract

Garmezy, B.; Borad, M.; Lin, C. C.; Chen, L. T.; Perez, C. A.; Kato, S.; Tam, B.; Severson, P.; Quah, C. S.; Harding, J. J.
Annals of Oncology (2023)

Fulltext@MSK | Save

Individual patient data (IPD) meta-analysis of randomised trials to compare efficacy of second-line fluoropyrimidine-based chemotherapy in advanced biliary tract cancer (BTC)

Meeting Abstract

Hyung, J.; Kang, M.; Kim, I.; Kim, P.; Ryoo, B. Y.; Cheon, J.; Ryu, H.; Lee, J. S.; Abou-Alfa, G. K.; Kim, J. W.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study

Meeting Abstract

Wasan, H. S.; Harding, J. J.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H.; Macarulla, T.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Journal Article

Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yanez, P.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y.; more...
Lancet (2023)

Fulltext@MSK | Save

Efficacy of HER2-targeted intraperitoneal (225)Ac α-pretargeted radioimmunotherapy for small-volume ovarian peritoneal carcinomatosis

Journal Article

Chung, S. K.; Vargas, D. B.; Chandler, C. S.; Katugampola, S.; Veach, D. R.; McDevitt, M. R.; Seo, S. H.; Vaughn, B. A.; Rinne, S. S.; Punzalan, B.; more...
Journal of Nuclear Medicine (2023)

Fulltext@MSK | Save

Nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: Analysis of number needed to treat and number needed to harm

Journal Article

Sugarman, R.; Betts, K. A.; Nie, X.; Hartman, J.; Nguyen, H.
Clinical Therapeutics (2023)

Fulltext@MSK | Save

Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up☆

Guidelines

Conroy, T.; Pfeiffer, P.; Vilgrain, V.; Lamarca, A.; Seufferlein, T.; O'Reilly, E. M.; Hackert, T.; Golan, T.; Prager, G.; Haustermans, K.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: An ACCENT/IDEA pooled analysis of seven trials

Journal Article

Taieb, J.; Sinicrope, F. A.; Pederson, L.; Lonardi, S.; Alberts, S. R.; George, T. J.; Yothers, G.; Van Cutsem, E.; Saltz, L.; Ogino, S.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Patient and clinician stakeholder perspectives on a patient portal questionnaire eliciting illness and treatment understanding and core health-related values

Journal Article

Rosa, W. E.; Gilliland, J.; McDarby, M.; Nelson, J. E.; Desai, A. V.; Epstein, A. S.
Palliative Medicine Reports (2023)

Fulltext@MSK | Save

Phase Ib/II study of the efficacy and safety of binimetinib (MEK162) plus panitumumab for mutant or wild-type RAS metastatic colorectal cancer

Journal Article

Van Cutsem, E.; Yaeger, R.; Delord, J. P.; Tabernero, J.; Siu, L. L.; Ducreux, M.; Siena, S.; Elez, E.; Kasper, S.; Zander, T.; more...
The Oncologist (2023)

Fulltext@MSK | Save